Imetelstat API is a pharmaceutical-grade telomerase inhibitor developed for the treatment of hematologic malignancies, including lower-risk myelodysplastic syndromes (MDS) and myelofibrosis. It is a first-in-class lipid-conjugated oligonucleotide that selectively inhibits telomerase activity, limiting the ability of malignant cells to maintain telomere length and continue uncontrolled proliferation.
By targeting telomerase, Imetelstat induces senescence and apoptosis in cancer cells while helping reduce abnormal hematopoietic cell growth. It represents an innovative targeted therapy for patients with specific bone marrow disorders.
Manufactured under WHO-GMP-certified facilities, our Imetelstat API is produced using advanced biopharmaceutical manufacturing processes to ensure exceptional purity, stability, and batch-to-batch consistency. Each batch undergoes comprehensive analytical testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Imetelstat API is used in the development of injectable oncology formulations for treating myelodysplastic syndromes (MDS), myelofibrosis, and other hematologic malignancies.
Imetelstat inhibits telomerase enzyme activity, preventing cancer cells from maintaining telomere length, which limits cell proliferation and promotes apoptosis.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Imetelstat API in commercial quantities for pharmaceutical and research applications with worldwide export support.
Get Bulk Quote via WhatsApp